Spyre Therapeutics (SYRE) Assets Average (2016 - 2026)
Spyre Therapeutics' (SYRE) quarterly Assets Average came in at $770.9 million in Q1 2026, up 30.85% YoY from $589.1 million in Q1 2025, and up 20.22% on a QoQ basis from $641.2 million in Q4 2025.
Spyre Therapeutics (SYRE) Assets Average (2016 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 11 years of Assets Average data on file, last reported at $770.9 million in Q1 2026.
- Quarterly Assets Average rose 30.85% year-over-year to $770.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $770.9 million (up 30.85% YoY) and the FY2025 annual result came in at $693.1 million, up 45.87% from the prior year.
- Assets Average climbed to $770.9 million in Q1 2026, from $641.2 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $770.9 million in Q1 2026 to a low of $61.8 million in Q1 2023.
- A 5-year average of $351.7 million and a median of $414.7 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average slumped 40.63% — and 2024, when it soared 571.1%.
- Tracing SYRE's Assets Average over 5 years: stood at $81.4 million in 2022, then jumped by 237.49% to $274.6 million in 2023, then surged by 87.49% to $514.8 million in 2024, then rose by 24.56% to $641.2 million in 2025, then climbed by 20.22% to $770.9 million in 2026.
- The last three Assets Average figures came in at $770.9 million (Q1 2026), $641.2 million (Q4 2025), and $521.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 968.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 968.48 Mn |
| Mar 31, 2026 | 770.87 Mn |
| Dec 31, 2025 | 641.19 Mn |
| Sep 30, 2025 | 521.72 Mn |
| Jun 30, 2025 | 554.31 Mn |
| Mar 31, 2025 | 589.13 Mn |
| Dec 31, 2024 | 514.79 Mn |
| Sep 30, 2024 | 428.58 Mn |
| Jun 30, 2024 | 461.83 Mn |
| Mar 31, 2024 | 414.73 Mn |
| Dec 31, 2023 | 274.56 Mn |
| Sep 30, 2023 | 225.40 Mn |
| Jun 30, 2023 | 147.99 Mn |
| Mar 31, 2023 | 61.80 Mn |
| Dec 31, 2022 | 81.36 Mn |
| Sep 30, 2022 | 99.14 Mn |
| Jun 30, 2022 | 94.94 Mn |
| Mar 31, 2022 | 96.55 Mn |
| Dec 31, 2021 | 119.49 Mn |
| Sep 30, 2021 | 138.02 Mn |